Evidence map›Paper›PMID 41135912›Full record

ArticleRespiratory medicine

Development of novel pegylated imidazobenzodiazepines as inhaled asthma drug candidates.

Ethan T Kowalczyk, Kayode M Medubi, Michelle J Meyer, Mubaraq A Toriola, Tyler J Haasch, Makena R Vesperman, Daniel A Webb, Douglas C Stafford, Gene T Yocum, Charles W Emala and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ethan T KowalczykDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Kayode M MedubiDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Michelle J MeyerDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Mubaraq A ToriolaDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Tyler J HaaschDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Makena R VespermanDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Daniel A WebbDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Douglas C StaffordDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States.
Gene T YocumDepartment of Anesthesiology, Columbia University, New York, NY, 10032, United States.
Charles W EmalaDepartment of Anesthesiology, Columbia University, New York, NY, 10032, United States.
Leggy A ArnoldDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States. Electronic address: arnold2@uwm.edu.

Funding

TO AWARD THE BASE PERIOD FOR NIMH PSYCHOACTIVE DRUG SCREENING PROGRAM (PDSP). BASE POP: 08/30/2023-08/29/2024.75N95023C00021 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN · 2023 to 2025
$9.0M
Anesthetics' Effects on Physiological Responses Modulated by Peripheral GABAA ReceptorsR35GM140880 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EMALA, CHARLES W · 2021 to 2025
$2.0M
Development of microencapsulated PI301 targeting lung GABAergic signalingR43HL162474 · NHLBI · PANTHERICS INCORPORATED · PI STAFFORD, DOUGLAS C. · 2022 to 2022
$256k
A novel asthma drug candidate targeting the GABAergic system in lung inflammationR41HL147658 · NHLBI · PANTHERICS INCORPORATED · PI ARNOLD, ALEXANDER · 2019 to 2019
$225k
NHLBI NIH HHS R41 HL147658NHLBI NIH HHS R43 HL162474NIDA NIH HHS 75N95023C00021NIGMS NIH HHS R35 GM140880
6 · The paper itself

Abstract

In this work, we identified a novel asthma drug candidate that upon nebulized administration reduced airway hyperresponsiveness in A/J mice comparable to the beta agonist albuterol. We identified this compound among synthesized pegylated imidazodiazepines with substituent variations in two positions. These compounds combine good affinity towards the gamma aminobutyric acid (A) receptors (GABA

Indexed as

Anti-Asthmatic AgentsAsthmaBenzodiazepinesPolyethylene GlycolsAdministration, InhalationAnimalsBronchodilator AgentsGuinea PigsIsoproterenolLungMaleMiceReceptors, GABA-ATracheaAnti-Asthmatic AgentsBenzodiazepinesBronchodilator AgentsIsoproterenolPolyethylene GlycolsReceptors, GABA-AAsthmaGABA(A) receptorImidazobenzodiazepinesMetabolismPegylation

Identifiers

PMID41135912
PMCPMC12667216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.